A revolutionary breakthrough could soon enable testing for Alzheimer's disease through a simple finger prick, potentially allowing for earlier diagnosis and treatment.
A new rapid test for urinary tract infections can quickly identify the most effective antibiotic for each patient, reducing diagnosis time by up to 24 hours and potentially decreasing the use of broad-spectrum antibiotics, thereby helping to combat antibiotic resistance.
Scientists have developed a highly accurate (96%) blood test for diagnosing Chronic Fatigue Syndrome (ME/CFS) using DNA folding technology, which could improve diagnosis and treatment, and may also aid in diagnosing long Covid.
Scientists have developed a low-cost, portable saliva biosensor that can detect BDNF levels in under three minutes, potentially aiding early diagnosis and monitoring of mental health conditions like depression and schizophrenia, with each test costing around $2.19.
Innovative startups and research groups are exploring the potential of menstrual blood as a noninvasive, at-home diagnostic tool for gynecological conditions like endometriosis, leveraging its unique cellular and molecular content to improve early detection and treatment, despite current funding and societal challenges.
A recent study shows that prostate cancers can be detected using shorter, more affordable scans, potentially improving early diagnosis and reducing healthcare costs.
Simone Gibertoni, CEO of Clinique La Prairie, discusses advancements in longevity, including AI-driven diagnostics and holistic wellness strategies, exploring the future of extending human lifespan in the context of the booming $2tn global wellness market.
Originally Published 5 months ago — by Hacker News
Research suggests that certain gait patterns, such as toe-walking or specific arm movements, could be indicators of autism, but these are not definitive and may be influenced by various factors. The article discusses the complexity of diagnosing autism based on physical behaviors and emphasizes the importance of tolerance and understanding of neurodiversity.
Waters Corp is acquiring a Becton Dickinson bioscience and diagnostics unit in a $17.5 billion stock-and-cash deal, aiming to expand its presence in clinical and diagnostic markets, while Becton Dickinson exits a tariff-sensitive segment to focus on core medtech. The deal, structured through a Reverse Morris Trust, will result in Waters owning 61% of the new company, with Becton Dickinson shareholders holding 39%, but has faced skepticism from investors due to execution risks.
Originally Published 6 months ago — by BD Newsroom
Waters Corporation and BD's Biosciences & Diagnostic Solutions are merging in a $17.5 billion deal to create a leading life science and diagnostics company, expanding their market reach, increasing recurring revenue, and delivering significant synergies and growth projections by 2025 and 2030.
Patients and doctors are increasingly using AI like ChatGPT for diagnoses and treatment advice, with some success, such as a Reddit user who found relief for a five-year jaw pain after AI suggested a solution. However, disagreements between experts and AI can pose challenges.
Scientists are exploring how the analysis of snot's color, consistency, and microbiome can provide valuable insights into health conditions like infections, allergies, and lung diseases, potentially leading to new diagnostic and treatment methods such as nasal microbiome transplants and personalized medicine approaches.
Research demonstrates that facial expressions can reveal internal cognitive states and predict task performance in macaques and mice, suggesting potential applications in diagnosing conditions like autism, ADHD, and dementia in humans, pending further validation.
Bill Gates shares his optimism about the fight against Alzheimer's disease, highlighting recent breakthroughs like blood-based diagnostic tests, new treatments, and increased research funding, which together offer hope for earlier detection and more effective interventions in the future.
Scientists at Mass General Brigham have developed LUCAS, a portable, highly accurate, and rapid bioluminescent test that detects viruses like HIV and COVID-19 in under 23 minutes, with potential to improve diagnostics especially in resource-limited settings.